Blocking a cell defense may help chemo work better in lab tests
Original title: NRF2 signaling drives chemoresistance in NSCLC and glioblastoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was done only in cells in a lab dish, not in people.
The short version
In lab dishes, one drug made tumor cells respond better to chemo.
What was studied. Scientists tested lung cancer and brain tumor cells in the lab. Some of these cells resisted the chemo drugs temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary and cisplatin. The team looked at why.
What they found. The resistant cells had high levels of a protein called NRF2. They also held a lot of a chemical called glutathione. A drug called BSO lowered that chemical. After that, the chemo drugs killed more of the resistant cells.
What this means, and what it doesn't
What it could mean: This points to one reason chemo stops working for some tumors. It gives scientists a new idea to test. Nothing here is ready for patients.
What it doesn't mean: This work was done only in cells in a dish. It was not tested in people or animals. It does not mean a new treatment is coming soon. It is not a promise of a cure. Many lab results never work the same way in people. This does not change the care you get today.
Source: PubMed, September 19, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.